Adalimumab concentration-based tapering strategy: as good as the recommended dosage.
作者信息
Mulleman Denis, Balsa Alejandro
机构信息
Department of Rheumatology, Université François-Rabelais de Tours, CNRS, UMR 7292, Tours, France.
Department of Rheumatology, Health Research Institute (IdiPAZ), Hospital Universitario La Paz, Madrid, Spain.
出版信息
Ann Rheum Dis. 2018 Apr;77(4):473-475. doi: 10.1136/annrheumdis-2017-212376. Epub 2018 Jan 6.
Abstract
摘要
相似文献
1
Adalimumab concentration-based tapering strategy: as good as the recommended dosage.
Ann Rheum Dis. 2018 Apr;77(4):473-475. doi: 10.1136/annrheumdis-2017-212376. Epub 2018 Jan 6.
2
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Cochrane Database Syst Rev. 2014 Sep 29(9):CD010455. doi: 10.1002/14651858.CD010455.pub2.
3
Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from STRASS study.
Ann Rheum Dis. 2020 Jul;79(7):e81. doi: 10.1136/annrheumdis-2019-215546. Epub 2019 May 2.
4
Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Imact of esidual Inflammation Detected via Imaging Tchniques, rug Levels and Patient Characteristics on the Outcome of Dose Taperng of Adalimumab in linical Remission Rheumatoid Arhritis () patients (PREDICTRA).
BMJ Open. 2018 Feb 28;8(2):e019007. doi: 10.1136/bmjopen-2017-019007.
5
Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Curr Med Res Opin. 2008 Aug;24(8):2229-40. doi: 10.1185/03007990802229548. Epub 2008 Jun 23.
6
Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.
Ann Rheum Dis. 2020 Aug;79(8):1023-1030. doi: 10.1136/annrheumdis-2020-217246. Epub 2020 May 13.
7
Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte .
Ann Rheum Dis. 2020 Jul;79(7):e82. doi: 10.1136/annrheumdis-2019-215609. Epub 2019 May 9.
8
Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
Cochrane Database Syst Rev. 2019 May 24;5(5):CD010455. doi: 10.1002/14651858.CD010455.pub3.
9
A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
Rheumatology (Oxford). 2017 Jun 1;56(6):973-980. doi: 10.1093/rheumatology/kex003.
引用本文的文献
1
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider.
RMD Open. 2022 Jun;8(2). doi: 10.1136/rmdopen-2022-002216.
2
Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults.
Ther Adv Musculoskelet Dis. 2021 Jun 16;13:1759720X211002685. doi: 10.1177/1759720X211002685. eCollection 2021.
3
The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring.
Front Immunol. 2021 Apr 15;12:636420. doi: 10.3389/fimmu.2021.636420. eCollection 2021.
4
Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations.
Eur J Clin Pharmacol. 2020 Oct;76(10):1417-1425. doi: 10.1007/s00228-020-02925-w. Epub 2020 Jun 9.
5
Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.
Clin Transl Sci. 2020 Jul;13(4):743-751. doi: 10.1111/cts.12760. Epub 2020 Apr 1.
6
Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.
Ann Rheum Dis. 2019 Sep;78(9):1285-1286. doi: 10.1136/annrheumdis-2018-214860. Epub 2019 Mar 18.
本文引用的文献
1
Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.
Clin Pharmacol. 2017 Oct 3;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017.
2
Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.
Ann Rheum Dis. 2018 Apr;77(4):484-487. doi: 10.1136/annrheumdis-2017-211781. Epub 2017 Sep 22.
3
Therapeutic Drug Monitoring of Biopharmaceuticals May Benefit From Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling.
Ther Drug Monit. 2017 Aug;39(4):322-326. doi: 10.1097/FTD.0000000000000389.
4
Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis.
Ther Drug Monit. 2017 Aug;39(4):364-369. doi: 10.1097/FTD.0000000000000421.
5
Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review.
Expert Opin Drug Metab Toxicol. 2017 Aug;13(8):843-857. doi: 10.1080/17425255.2017.1353602. Epub 2017 Jul 17.
6
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.
7
Immunoassays for Measuring Serum Concentrations of Monoclonal Antibodies and Anti-biopharmaceutical Antibodies in Patients.
Ther Drug Monit. 2017 Aug;39(4):316-321. doi: 10.1097/FTD.0000000000000419.
8
Rationale for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Diseases.
Ther Drug Monit. 2017 Aug;39(4):339-343. doi: 10.1097/FTD.0000000000000410.
9
Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis.
Arthritis Rheumatol. 2017 Jan;69(1):108-113. doi: 10.1002/art.39841. Epub 2016 Nov 28.
10
Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up.
Rheumatology (Oxford). 2016 Jan;55(1):143-8. doi: 10.1093/rheumatology/kev298. Epub 2015 Aug 31.
Zotero 插件